When importing medicines in foreign packaging that were manufactured for the markets of other countries, the distribution of these imported medicines is carried out in accordance with general rules.
As the Ukrainian Agency for Medicines notes, the possibility of importing medicines in foreign packaging is permitted for the entire duration of martial law and for 6 months following its termination. This provision is intended to ensure the supply of medicines to all healthcare facilities, including hospitals and pharmacies.
“The law does not require any additional notifications or special confirmations that a batch is being imported for a specific healthcare facility; the distribution of such medicines is carried out in accordance with general regulations,” the Ukrainian State Agency for Medicines clarifies.
At the same time, the agency notes that a drug in foreign packaging must be completely identical to the one registered in Ukraine—that is, it must match 100% in terms of the qualitative and quantitative composition of active and excipients, packaging, and must have the same approved manufacturing sites, specifications, quality control methods, and expiration dates, among other things.
However, differences in the labeling and design of the packaging itself are permitted.
Each package must be accompanied by a package insert approved in Ukraine.
“The responsibility to provide this accompanying documentation rests with the importer,” emphasizes the Ukrainian Agency for Medicines.
IMPORT, MARTIAL LAW, MEDICINES, PHARMACEUTICALS, Ukrainian Agency for Medicines
As a result of an enemy attack, the Kusum pharmaceutical plant in Sumy was destroyed, and one employee was killed.
“This morning, the production facility of the Kusum pharmaceutical company in Sumy was destroyed as a result of an enemy attack. Unfortunately, the attack claimed the life of company employee Yevgeny Vladimirovich Miroshnichenko, who had worked in the plant’s engineering department since 2009. ‘Kusum’ extends its sincere condolences to his family and loved ones,” the company stated on its website.
The company reports that ‘Kusum’ continues to operate.
” In addition to its production facilities in Ukraine, the company has manufacturing sites in India—in Indore and Bhiwadi. “This will allow us, in the absence of artificial regulatory barriers, to restructure our processes and work to ensure uninterrupted supplies of medicines to Ukraine,” the pharmaceutical company stated.
Bringing pharmaceutical production into compliance with European requirements demands significant investments from Ukrainian pharmaceutical manufacturers, which could lead to higher production costs, according to Anatoliy Reder, CEO of the pharmaceutical company “Interchem.”
“We are operating within the paradigm that our country is currently moving toward—alignment with European requirements. We must understand that compliance with European standards, EU directives, and the principles and approaches currently in effect in Europe will require significant additional investments from us—in production, regulatory processes, research, and so on. In other words, this involves enormous additional costs in order to meet, within a relatively short period of time, the requirements that are currently the norm in the European Union. With a gradual transition to these requirements, it must be acknowledged that production costs will rise significantly,” he said in an interview with the “Interfax-Ukraine” news agency.
As Reder noted, compliance with European standards—particularly those incorporated into Ukraine’s law on medicinal products—will automatically require additional investments, which will inevitably lead to price increases.
“We need to speak openly about this. You can’t make pills out of thin air. If additional controls are needed, additional costs will be incurred. Today, we monitor every batch of manufactured products throughout their entire shelf life—something that wasn’t required before—and this involves hundreds and thousands of manufactured batches and, consequently, enormous costs. The additional control points in production required of us by European Union legislation—this means additional equipment, additional laboratory staff, and additional production processes—represent objectively large-scale investments. These costs will inevitably lead to price increases,” he stated.
The pharmaceutical company “JSC Galichpharm” (Lviv) produced 3.934 million packages of finished pharmaceutical products in the second quarter of 2026, worth approximately 981.424 million UAH.
According to the company’s disclosure in the National Securities and Stock Market Commission (NSSMC) disclosure system, the average cost per package of medicines is 213.18 UAH for injectables, 52.11 UAH for infusions, 117.25 UAH for liquids and syrups, and 52.6 UAH for tablets.
Galichpharm’s total revenue for the second quarter of 2026 amounted to 354.394 million UAH. Total exports reached 115.4 million UAH, or 48.3% of total sales.
Currently, the company supplies products to the Ukrainian market and exports them to Kazakhstan, Uzbekistan, Latvia, Australia, and other countries.
As previously reported, “Galichpharm” (Lviv) produced 22.098 million packages of medicines in 2025 and sold finished products worth 1.774 billion UAH. The company then reported a net loss of 1.151 billion UAH, compared to a net profit of 13.705 million UAH in 2024 (-39% compared to 2023).
As previously reported, in May 2025, the Commercial Court of Lviv Oblast opened bankruptcy proceedings against the pharmaceutical manufacturer JSC “Galichpharm” based on claims filed by LLC “Sky-Development” in the amount of 479.262 million UAH. On April 21, 2025, Sky-Development LLC acquired from JSC “Bank Finansy i Kredit” the rights to claims against JSC “Galichpharm” under loan agreements and security agreements.
The investment company “Sky-Development” won an open auction organized by the Deposit Guarantee Fund for Individuals and acquired the claims of the insolvent JSC “Bank ‘Finansy i Kredit’” under ten loan agreements with leading Ukrainian pharmaceutical companies: JSC “Galichpharm” and JSC “Kyivmedpreparat.” According to Sky Development, the total amount of its claims exceeds 3.5 billion UAH.
For their part, “Kyivmedpreparat” and “Galichpharm” stated that the information disseminated by Sky Development Investment Company is “inaccurate, manipulative, and shows signs of a deliberate attempt to discredit the companies’ operations.” In particular, both companies denied having “multi-billion debts” to “Sky Development.” The pharmaceutical companies characterized the statements by “Sky Development” LLC as “an attempt to illegally and artificially create non-existent creditor debt for a possible future hostile takeover of the companies.”
EXPORTS, Galichpharm, MANUFACTURING, MEDICINES, PHARMACEUTICALS
Pharmacy sales of drugs in Ukraine from January through June 2026 increased by 19.52% in monetary terms compared to the same period last year, reaching nearly 97.918 billion UAH.
According to a report by Business Credit to the Interfax-Ukraine news agency, citing research findings, sales of medicines in volume terms also rose—by 4.9%, to nearly 418.711 million packages.
The weighted average retail price of pharmaceuticals for the first half of the year was 233.85 UAH per package, which is 13.96% higher than the figure for January–June 2025.
Thus, the pharmaceutical segment demonstrated growth not only due to higher prices but also thanks to an increase in the number of packages sold. This distinguishes it from the pharmacy market as a whole, where sales in physical terms declined by 5.8% over the six-month period.
In the first quarter of 2026, pharmaceutical sales rose by 13.9% in monetary terms—to over 48.426 billion UAH—and by 4.85% in volume terms—to nearly 211.947 million packages.
In 2025, Ukrainian pharmacies sold medicines worth 170.318 billion UAH, which is 12.79% more than the previous year. The volume of sales then decreased by 0.2% to 808.546 million packages.
Ukrainian pharmaceutical manufacturers expect the government to facilitate the launch of tools for 2D verification of medicines in Ukraine.
As Petro Bagriy, president of the Association of Ukrainian Drug Manufacturers (AULU), told the “Interfax-Ukraine” news agency, this specifically involves facilitating pharmaceutical manufacturers’ access to software that will allow them to verify pharmaceutical products using a 2D code compatible with European systems, as well as the introduction of certain tax incentives for the purchase of the necessary equipment.
Bagriy noted that these issues were discussed during the most recent working meeting of members of the newly established “National Organization for the Verification of Medicines” (NOVLM).
“There is a provision in the new law on medicines stipulating that 2D coding of medicines must be operational in Ukraine by 2028. Such verification is one of the tools for combating counterfeit medicines. Ukraine is integrating into the EU, where this is a mandatory requirement, as only medicines verified by a 2D code are permitted for sale within the EU. Moreover, when exporting their medicines, Ukrainian pharmaceutical manufacturers label their products with 2D codes. But this is expensive; it requires significant investment in equipment and the renovation of packaging facilities,” he said.
The president of the Association of Pharmaceutical Manufacturers of Ukraine (AVLU) believes that not only pharmaceutical manufacturers but also distributors, pharmacies, and healthcare facilities that purchase medicines should participate in the launch of the system.
“We want to build a completely transparent system that will fully satisfy all participants, discriminate against no one, and provide equal rights and opportunities. In addition, it is important for the system to be fully integrated into the EU. We are discussing the possibility of engaging a software developer who will support the 2D verification—specifically, the one who developed it for EU countries—so that our product is fully integrated into all EU markets,” he emphasized.
Bagriy noted that, as a result, the QR codes used in Ukraine will be accepted in Europe, which will help promote Ukrainian medicines in European markets and also simplify the circulation of imported medicines in Ukraine.
“For example, ‘Farmaka,’ which will apply its code to its products, will find it easier to sell them in European pharmacies, and ‘Sanofi’ products will be easier to verify in Ukraine,” explained the president of the AULU.
He noted that “there is an initiative to exempt equipment imported for the implementation of the 2D-coding program for medicines from import duties and VAT.”
In addition, Bagriy reported that the Ministry of Health “is helping to negotiate a preferential price for the software in order to facilitate the financing of this project.”
“We have made a request, and the Minister of Health has promised us support so that we can gain access to software that has already been developed in the EU and be able to use it at a discounted price,” he said.
The president of the Association of Pharmaceutical Companies of Ukraine noted that the pilot system is scheduled to launch on January 1, 2027, and the system is expected to be fully operational as of January 1, 2028.
As previously reported, five pharmaceutical industry associations have registered the “National Organization for the Verification of Medicines” (NOVLM) to prevent and combat the circulation of counterfeit medicines in Ukraine in cooperation with European counterparts and the European Organization for the Verification of Medicines.
